PTC Therapeutics

Press Releases

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. PTC Therapeutics disavows any obligation to update the information contained in such press releases after the date of their issuance.

 
Press Releases
  Date Title and Summary View
May 9, 2018
SOUTH PLAINFIELD, N.J., May 9, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and reported financial results for the first quarter ending March 31, 2018. "Over the past twenty years it has been our mission to bring clinically differentiated therapies to patients with rare disorders," said Stuar...
May 1, 2018
SOUTH PLAINFIELD, N.J., May 1, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its first quarter 2018 financial results and provide an update on the company's business and outlook on Wednesday, May 9, 2018 at 4:30 p.m. (ET) after closing of the market. ...
Apr 30, 2018
SOUTH PLAINFIELD, N.J., April 30, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company update at the Bank of America Merrill Lynch 2018 Health Care Conference, on Tuesday, May 15th at 2:20 p.m. PT The presentation will be webcast live on the Events and Presentations page under the...
Apr 27, 2018
SOUTH PLAINFIELD, N.J., April 27, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on April 24, 2018 it approved non-statutory stock options to purchase an aggregate of 172,150 shares of its common stock to 25 new employees and a restricted stock unit for 4,000 shares of its common stock to one of the new employees.  ...
Apr 24, 2018
SOUTH PLAINFIELD, N.J., April. 24, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the presentation of preliminary data from Part 1, the dose finding portion, of the ongoing FIREFISH clinical trial. The open-label trial is evaluating RG7916, an oral survival motor neuron 2 (SMN2) splicing modifier, in Type 1 SMA patients....
Apr 12, 2018
SOUTH PLAINFIELD, N.J., April 12, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (Nasdaq: PTCT) announced today that the underwriters of its previously announced public offering of 4,000,000 shares of its common stock, which closed on April 3, 2018, have exercised in full their option to purchase an additional 600,000 shares at the public offering pri...
Apr 9, 2018
SOUTH PLAINFIELD, N.J., April 9, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced that it will hold its R&D Day on Tuesday, April 17, 2018 from 12:00 p.m. to 5:00 p.m. ET in New York City. Members of PTC's senior management and research teams will provide a corporate update and in-depth reviews of the Company's commercial produc...
Apr 4, 2018
SOUTH PLAINFIELD, N.J., April 4, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) and the CHDI Foundation, Inc. (CHDI) today announced a research collaboration to advance PTC's Huntington's disease program. The program is optimizing small-molecule compounds—identified using PTC's splicing technology platform—that decrease the ...
Mar 28, 2018
SOUTH PLAINFIELD, N.J., March 28, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (Nasdaq: PTCT) announced today the pricing of a public offering of 4,000,000 shares of its common stock at a public offering price of $27.04 per share, before underwriting discounts. All of the shares in the offering are to be sold by PTC. In addition, PTC has granted the...
Mar 27, 2018
SOUTH PLAINFIELD, N.J., March 27, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (Nasdaq: PTCT) announced today that it is commencing a public offering of 4,000,000 shares of its common stock. All of the shares in the offering are to be sold by PTC. PTC intends to grant the underwriters an option for a period of 30 days to purchase up to an additional...
Page:
1
... NextLast
= add release to Briefcase
You are now leaving this website. If you would like to continue, click Continue.
CancelContinue